FDA Approves VORICONAZOLE — PAI Holdings, LLC dba PAI Pharma

# FDA Approves PAI Pharma's Generic Voriconazole Injection PAI Holdings, LLC dba PAI Pharma received FDA approval for its generic voriconazole intravenous injection (ANDA220043), expanding the competitive landscape for this widely-used antifungal treatment and potentially reducing costs for healthcare systems and patients. The approval is expected to increase price competition in the intravenous antifungal market, benefiting hospital formularies and payers while establishing PAI Pharma as a supplier of this critical infectious disease medication.